Detalhe da pesquisa
1.
Empagliflozin after Acute Myocardial Infarction.
N Engl J Med
; 390(16): 1455-1466, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587237
2.
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.
Circulation
; 149(21): 1627-1638, 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38581389
3.
Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry.
Am J Ther
; 31(1): e1-e12, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231576
4.
Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
J Thromb Thrombolysis
; 52(4): 1195-1206, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33929686
5.
Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study.
Eur J Epidemiol
; 34(3): 247-258, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30353266
6.
Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology.
Cardiovasc Diabetol
; 14: 133, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26427624
7.
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
J Am Coll Cardiol
; 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588929
8.
Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.
Eur Heart J
; 33(22): 2865-72, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22843446
9.
NGAL as Biomarker of Clinical and Subclinical Damage of Kidney Function after Coronary Angiography.
Diagnostics (Basel)
; 13(6)2023 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36980488
10.
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.
Can J Cardiol
; 39(10): 1315-1324, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37116789
11.
Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model.
Eur J Prev Cardiol
; 29(2): 328-339, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33623999
12.
Potential for optimizing management of obesity in the secondary prevention of coronary heart disease.
Eur Heart J Qual Care Clin Outcomes
; 8(5): 568-576, 2022 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34315174
13.
Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.
Eur J Prev Cardiol
; 28(4): 370-379, 2021 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33966079
14.
Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
Open Heart
; 7(1): e001202, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32257246
15.
Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURoObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry.
J Hypertens
; 37(10): 2015-2023, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31246889
16.
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.
Circ Cardiovasc Qual Outcomes
; 12(11): e005858, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707826
17.
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.
Eur J Prev Cardiol
; 26(8): 824-835, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739508
18.
Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey.
Int J Cardiol
; 272: 20-25, 2018 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30172478
19.
Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS).
J Atheroscler Thromb
; 23(5): 567-87, 2016 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26632163
20.
Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys.
Eur J Prev Cardiol
; 23(15): 1618-27, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27084894